Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company.[1] At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial for edasalonexent is enrolling boys affected by Duchenne .
Public | |
Traded as | NASDAQ: CATB Russell Microcap Index component |
Industry | Pharmaceuticals |
Founded | 2008 |
Headquarters | Cambridge, Massachusetts |
Key people | Jill C. Milne, Ph.D. (CEO)
Joanne M. Donovan, M.D., Ph.D. (Chief Medical Officer) Andrew Nichols, Ph.D. (Chief Scientific Officer), Deirdre A. Cunnane (Chief Legal Officer) |
Products | Orally-delivered pharmaceuticals |
Number of employees | 24 (March 2019) |
Website | www.catabasis.com |
In Catabasis’s Phase 2 MoveDMD clinical trial and open-label extension, edasalonexent was shown to preserve muscle function as assessed by the North Star Ambulatory Assessment and Timed Function Tests compared with the rate of change during an off-treatment control period. It also showed a significant decrease in CRP, muscle enzymes including CK, and decrease in heart rate to age-normative values .
In January 2020, Catabasis announced the pricing of an underwritten public offering of 4,600,000 shares of common stock priced at $5.00 per share. The gross proceeds are expected to be approximately $23 million, before deducting the underwriting discount and other offering expenses.[2][3]
References
- "Our Story - Our Company - Catabasis". www.catabasis.com. Retrieved 2017-02-17.
- "Bloomberg - Are you a robot?". www.bloomberg.com. Retrieved 2020-03-12.
- "Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering". www.nasdaq.com. Retrieved 2020-03-12.